Clinical Trials · NCT02115282
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 608
- Start date
- Mar 2014
- Locations
- 655 sites, United States, South Africa
- Primary endpoint
- Progression-free Survival (PFS)